KRAS and cancer: Recently, Salem and his colleagues sought to understand the interaction of IO biomarkers [microsatellite instability-high (MSI-H)/mismatch repair deficit status, tumor mutational burden (TMB), and programmed death ligand 1 (PD-L1)] and KRAS variant (KRASG12C) using the next-generation sequencing analysis in the retrospective study of different types of cancer [60].